Proactive Investors - Run By Investors For Investors

Genprex to present at the Singular Research Summer Solstice conference

The biopharmaceutical company is making great strides toward developing its non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex
A researcher in a lab
Investors can hear Genprex CEO Rodney Varner talk about Oncoprox, which is in Phase 2 clinical trials

Genprex Inc (NASDAQ:GNPX), a clinical-stage gene-therapy company, announced Thursday that CEO Rodney Varner will present at the Singular Research Summer Solstice 2018 in New York City.

Varner will be presenting Thursday at 10.40 am ET at the high-profile conference in the small- and micro-cap space.

The Austin, Texas-based biopharmaceutical company is making great strides toward developing its non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex.

Varner earlier told Proactive Investors that Oncoprox is in Phase 2 of clinical trials, and next steps are to meet with the FDA about best pathways forward to an approval.

The company recently went public, raising $6.4mln. Varner said the biopharma will use the funds to continue clinical trials and expand and/or accelerate development programs into additional drug combinations.

Investors will be tuning into the conference for more details about progress on Oncoprox.

Investor excitement about the lung cancer-fighting, gene-therapy drug sent Genprex stock more than 1% higher to US$7.39 on Thursday's premarket action.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

View full GNPX profile View Profile

Genprex, Inc. Timeline

Related Articles

scientist at petrie dish
May 15 2019
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)
skin
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
A double helix and a medical person
March 07 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use